Sermorelin — Wolverine Health

How it works

The most clinically tested GH-stimulating peptide in this class. It's a synthetic fragment of natural GHRH — the signal your hypothalamus sends to trigger pituitary GH release. Once marketed as Geref for GH deficiency diagnostics in children. The clinical development history is real; so are the limitations: it works on a declining pituitary, so age and baseline function determine the ceiling.

FDA status: Previously marketed as Geref (withdrawn from commercial market). No current approved indication. Compoundable by 503A pharmacies as it is not an FDA-approved drug with an active NDA.
WADA status: Permitted in sport
Route: subcutaneous injection

Key studies

Sermorelin: a better approach to management of adult-onset GH insufficiency — Walker et al.

Sermorelin (GHRH 1-29) stimulates GH secretion via pituitary GHRH receptors and has been studied as a diagnostic and therapeutic agent for growth hormone insufficiency in adults.

Wolverine Health is building physician-supervised peptide protocols. Get early access.

Join the waitlist

Research on Sermorelin

Growth hormone secretagogues: the peptides that turn your own growth hormone back up

WADA

CJC-1295, ipamorelin, sermorelin, and tesamorelin share one job — getting your own pituitary to release more growth hormone, the repair-and-recovery signal that fades after your twenties. Here is the appeal, the two peptide families inside the class, and how far the human proof actually goes.

Sermorelin vs tesamorelin: which growth-hormone peptide is the right tool for you

WADA

Sermorelin and tesamorelin both nudge your pituitary to make more growth hormone. One targets deep visceral fat with a real Phase 3 behind it; the other is the gentler GH-axis nudge with an FDA past. Here's which one fits which goal — and why one is still an approved drug and the other isn't.

Sermorelin: the older growth hormone peptide that still has defenders

WADA

Sermorelin is the growth-hormone peptide with a real FDA past — and a clever way of working: it nudges your own gland to make more GH instead of overriding it. Here's what it could do for you, how far the human proof actually goes, and why its availability isn't waiting on the July FDA vote.

Sermorelin: the growth-hormone peptide that was a real FDA drug — twice

WADA

Sermorelin is the rare longevity peptide with an actual FDA past: sold as Geref, first as a diagnostic and then as a treatment for kids who couldn't make enough growth hormone. Here's what it is, what the human evidence covers, and where it sits with the FDA and WADA now.